Cargando…
New developments in the anti-neoplastic drug management of ovarian cancer
Over the past several years, there have been a number of relevant evidence-based randomized trials that have the potential to change the standard management paradigm in the malignancy of ovarian cancer and (most importantly) enhance clinically relevant outcomes. This commentary will briefly review t...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Faculty of 1000 Ltd
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816763/ https://www.ncbi.nlm.nih.gov/pubmed/24273649 http://dx.doi.org/10.12703/P5-48 |
| _version_ | 1782477980201648128 |
|---|---|
| author | Markman, Maurie |
| author_facet | Markman, Maurie |
| author_sort | Markman, Maurie |
| collection | PubMed |
| description | Over the past several years, there have been a number of relevant evidence-based randomized trials that have the potential to change the standard management paradigm in the malignancy of ovarian cancer and (most importantly) enhance clinically relevant outcomes. This commentary will briefly review these trials. |
| format | Online Article Text |
| id | pubmed-3816763 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | Faculty of 1000 Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-38167632013-11-22 New developments in the anti-neoplastic drug management of ovarian cancer Markman, Maurie F1000Prime Rep Review Article Over the past several years, there have been a number of relevant evidence-based randomized trials that have the potential to change the standard management paradigm in the malignancy of ovarian cancer and (most importantly) enhance clinically relevant outcomes. This commentary will briefly review these trials. Faculty of 1000 Ltd 2013-11-01 /pmc/articles/PMC3816763/ /pubmed/24273649 http://dx.doi.org/10.12703/P5-48 Text en © 2013 Faculty of 1000 Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes |
| spellingShingle | Review Article Markman, Maurie New developments in the anti-neoplastic drug management of ovarian cancer |
| title | New developments in the anti-neoplastic drug management of ovarian cancer |
| title_full | New developments in the anti-neoplastic drug management of ovarian cancer |
| title_fullStr | New developments in the anti-neoplastic drug management of ovarian cancer |
| title_full_unstemmed | New developments in the anti-neoplastic drug management of ovarian cancer |
| title_short | New developments in the anti-neoplastic drug management of ovarian cancer |
| title_sort | new developments in the anti-neoplastic drug management of ovarian cancer |
| topic | Review Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816763/ https://www.ncbi.nlm.nih.gov/pubmed/24273649 http://dx.doi.org/10.12703/P5-48 |
| work_keys_str_mv | AT markmanmaurie newdevelopmentsintheantineoplasticdrugmanagementofovariancancer |